Similar articles for PMID: 30061269

1

Cite

Share

Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience.

Sbrana A, Biasco E, Paolieri F, Palesandro E, Caserta C, Iacovelli R, Detti B, Santini D, Mosca A, Morelli F, Fornarini G, De Giorgi U, Masini C, Galli L. Sbrana A, et al. Anticancer Res. 2018 Aug;38(8):4913-4918. doi: 10.21873/anticanres.12807. Anticancer Res. 2018. PMID: 30061269

Cite

Share

2

Cite

Share

Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.

Matrana MR, Bathala T, Campbell MT, Duran C, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Tannir NM. Matrana MR, et al. BJU Int. 2016 Aug;118(2):264-71. doi: 10.1111/bju.13374. Epub 2015 Dec 13. BJU Int. 2016. PMID: 26573089 Free PMC article.

Cite

Share

3

Cite

Share

A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma.

Kim MJ, Park SH, Lee JL, Lee SH, Lee SJ, Lim HY. Kim MJ, et al. BMC Urol. 2016 Aug 2;16(1):46. doi: 10.1186/s12894-016-0163-5. BMC Urol. 2016. PMID: 27484998 Free PMC article.

Cite

Share

4

Cite

Share

Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients.

Poprach A, Fiala O, Chloupkova R, Melichar B, Lakomy R, Petrakova K, Zemanova M, Kopeckova K, Slaby O, Studentova H, Kopecký J, Kiss I, Finek J, Dusek L, Buchler T. Poprach A, et al. Anticancer Res. 2018 Jan;38(1):449-456. doi: 10.21873/anticanres.12243. Anticancer Res. 2018. PMID: 29277808

Cite

Share

5

Cite

Share

[First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].

Maráz A, Bodrogi I, Csejtei A, Dank M, Géczi L, Küronya Z, Mangel L, Petrányi A, Szûcs M, Bodoky G. Maráz A, et al. Magy Onkol. 2013 Sep;57(3):173-6. Epub 2013 Aug 9. Magy Onkol. 2013. PMID: 24107823 Free article. Hungarian.

Cite

Share

6

Cite

Share

Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.

Xie M, He CS, Huang JK, Lin QZ. Xie M, et al. Eur J Cancer. 2015 Mar;51(5):595-603. doi: 10.1016/j.ejca.2015.01.005. Epub 2015 Jan 21. Eur J Cancer. 2015. PMID: 25618828 Clinical Trial.

Cite

Share

7

Cite

Share

Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.

McAlister RK, Aston J, Pollack M, Du L, Koyama T, Chism DD. McAlister RK, et al. Oncologist. 2018 Jun;23(6):686-692. doi: 10.1634/theoncologist.2017-0578. Epub 2018 Feb 27. Oncologist. 2018. PMID: 29487220 Free PMC article.

Cite

Share

8

Cite

Share

Predictors of Long-Term Response With Pazopanib in Patients With Advanced Renal-Cell Carcinoma.

Park J, Jiao X, Ghate S, Wilson T, Ahmad QI, Vogelzang NJ. Park J, et al. Clin Genitourin Cancer. 2018 Aug;16(4):293-297. doi: 10.1016/j.clgc.2018.03.005. Epub 2018 Mar 23. Clin Genitourin Cancer. 2018. PMID: 29653813 Free article.

Cite

Share

9

Cite

Share

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.

Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, Zarba JJ, Gladkov OA, Lee E, Szczylik C, McCann L, Rubin SD, Chen M, Davis ID. Sternberg CN, et al. Eur J Cancer. 2013 Apr;49(6):1287-96. doi: 10.1016/j.ejca.2012.12.010. Epub 2013 Jan 12. Eur J Cancer. 2013. PMID: 23321547 Clinical Trial.

Cite

Share

10

Cite

Share

Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.

Bianconi M, Faloppi L, Loretelli C, Zizzi A, Giampieri R, Bittoni A, Andrikou K, Del Prete M, Burattini L, Montironi R, Scartozzi M, Cascinu S. Bianconi M, et al. Oncotarget. 2016 Jun 21;7(25):37599-37607. doi: 10.18632/oncotarget.9229. Oncotarget. 2016. PMID: 27175586 Free PMC article.

Cite

Share